Direkt zum Inhalt
Merck

Ontogeny of ethosuximide action against two seizure models in rats is different.

Life sciences (1998-08-11)
P Mares
ZUSAMMENFASSUNG

Action of ethosuximide (ESI) against two types of experimental seizures elicited by systemic administration of pentylenetetrazol (PTZ) and characterized by spike-and-wave activity in the EEG was studied in immature rats 18 and 25 days old, i.e. in such age groups where these age-dependent seizures could be reliably induced. Pretreatment with ESI in doses of 62.5 and 125 mg/kg i.p. suppressed episodes of spike-and-wave rhythm (rhythmic metrazol activity) elicited by a 40-mg/kg dose of PTZ in both age groups in a dose-dependent manner. Minimal metrazol seizures induced by higher dose of PTZ (70 mg/kg i.p.) were similarly suppressed by ESI in 25-day-old rats only. In 18-day-old animals ESI did not exhibit an anticonvulsant effect. These results speak against the adequacy of minimal metrazol seizures as a model of human absences. In addition, different development of ESI action against two types of experimental seizures suggests a possibility that there is more than one mechanism of action of ESI.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Ethosuximid